Current Status and Future Perspectives on Machine Perfusion: A Treatment Platform to Restore and Regenerate Injured Lungs Using Cell and Cytokine Adsorption Therapy

Cells

Franziska Olm¹  Sandra Lindstedt¹  Gabriel Hirdman¹  Anna Niroomand² 

[1] Lund Stem Cell Center, Lund University, 22242 Lund, Sweden;Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA;

关键词: lung transplantation;    EVLP;    machine perfusion;    cell therapy;    mesenchymal stromal cells;    extracellular vesicles;   

DOI  :  10.3390/cells11010091

来源: DOAJ

【 摘 要 】

Since its advent in the 1990′s, ex vivo lung perfusion (EVLP) has been studied and implemented as a tool to evaluate the quality of a donor organ prior to transplantation. It provides an invaluable window of opportunity for therapeutic intervention to render marginal lungs viable for transplantation. This ultimately aligns with the need of the lung transplant field to increase the number of available donor organs given critical shortages. As transplantation is the only option for patients with end-stage lung disease, advancements in technology are needed to decrease wait-list time and mortality. This review summarizes the results from the application of EVLP as a therapeutic intervention and focuses on the use of the platform with regard to cell therapies, cell product therapies, and cytokine filtration among other technologies. This review will summarize both the clinical and translational science being conducted in these aspects and will highlight the opportunities for EVLP to be developed as a powerful tool to increase the donor lung supply.

【 授权许可】

Unknown